How We
Have Impact
Strategy Advisement
Characterized by deep understanding of the drug pricing landscape, we specialize in advising the biopharmaceutical industry as it navigates complex drug pricing and market access policies, including but not limited to policy anticipation, risk mitigation, and identifying opportunities.
Future Solutioning
Our expertise extends to future planning for biopharmaceutical companies, examining alternatives to MFN, 340B reforms, PBM reforms, data transparency and what’s next for Medicare Part D.
Retained Subject Matter Expertise
The biopharmaceutical industry relies upon us as trusted advisors, frequently retained for our expertise in the most pressing issues facing innovative medicines, including, but not limited to MFN, IRA, MFP strategy, 340B, GTN revenue leakage, as well as GENEROUS, GLOBE and GUARD.
Agency and Hill Education
We provide detailed 340B advisement to agency and hill leaders, help small and emerging biotech evaluate impacts of MFN policies, and author policy informing research white papers on salient drug pricing topics facing the biopharmaceutical industry.
Stakeholder Engagement
We have a track record of enabling our biopharmaceutical clients to understand and anticipate needs and interests across their diverse spectrum of stakeholders, advising on stakeholder engagement strategies that advance the organization’s commitment to innovative medicines.
Policy-informed Product Life Cycle Planning
Our combined market access business acumen, subject matter expertise, and deeply informed knowledge of the current healthcare landscape shape our product lifecycle planning advisory, grounded in evolving drug pricing policy.
Public Speaking and Guest Lecturer
We are frequently included in industry events, forums, conferences and even in higher education to bring greater understanding and insights to conversations surrounding drug pricing and drug valuation.
Staff Training
Our expertise also extends to staff briefings and trainings for life sciences consultancies as well as biopharmaceutical companies. When building knowledge and comprehension of drug policy is advantageous, Aery Policy and Access Partners can design a program to equip your team in building competencies.
